Acadesine
Phase 3Small molecule
Merck & Co.Acadesine is one of 38 small molecule programs targeting Coronary Artery Bypass. It is currently in Phase 3.
1
Indications
2
Total Trials
0
Active Trials
37
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
148 competitors in Coronary Artery Bypass
#DrugCompanyPhaseTrials
1Crestor
AstraZenecaPhase 3
Farxiga
AstraZenecaPhase 3
Cyklokapron
AAmring
Phase 3
Arixtra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Effient
CCosette Pharmaceuticals, Inc.
Phase 3
Aggrastat
MMedicure
Phase 3
Bactroban
PPadagis LLC
Phase 3
Glargine Insulin
AstraZenecaPhase 3
Iron Sulphate
PPierre Fabre Pharma GmbH
Phase 3
Low-Dose Aspirin
PPharmaEssentia Japan K.K.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Acadesine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company